Physician profile
Amy M Moschell
NPI 1679575823
$1,971.24
in general payments reported to CMS, 2019-2025
20 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $134 · 2021: $346 · 2022: $293 · 2023: $185 · 2024: $353 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.41 | 2019-2025 | |
| Oyster Point Pharma, INC. | $263.65 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $228.48 | 2020-2023 | |
| Allergan, INC. | $222.02 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $150.45 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $129.22 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $117.45 | 2021-2022 | |
| Amgen INC. | $91.06 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $63.40 | 2022-2025 | Tryptyr, Rocklatan |
| Bausch & Lomb Americas INC. | $58.51 | 2023-2025 | Miebo, Xiidra |
| Astellas Pharma US INC | $52.19 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $47.92 | 2019-2021 | |
| Shire North American Group INC | $29.94 | 2019 | |
| Apellis Pharmaceuticals, INC. | $27.10 | 2025 | Syfovre |
| Harrow Eye, LLC | $26.65 | 2024 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.12 | 2022 | |
| Dompe US, INC. | $20.51 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Horizon Therapeutics Plc | $15.52 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Moschell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.